HALF YEAR RESULTS 2022
Andreas Eckert, CEO
11 August 2022
1
A Diversified Global Specialist for Radioactive Applications
ISOTOPE
PRODUCTS
Industry
Radiation
Sources
Services
Trade
Disposal
MEDICAL
Medicine
Medical Devices
Pharmaceuticals
Lab Devices
Engineering
Others
Group Items/
Pipeline
Holding
Pentixa
Myelo
Special projects
Engine
+++
106.8 million EUR Revenues in Q2 2022 | |
2 | 15.4 million EUR Net Income |
957 Employees (Headcounts)
19 Sites Worldwide
Results Q2-2022
(EUR million)
Since January 3rd, 2022
Tecnonuclear
3 Buenos Aires
Revenues | 106.8 |
Net Income | 15.4 |
NI/ Sales = 14%
2%
9%
43%
46%
America | Europe | Asia | Middle East & Africa | |
Slides only for illustration - the spoken word shall be binding
Growing Profits,
Growing Dividends
Dividend/ share in EUR
(share splitt adjusted)
Net Income in mm EUR | x 2,5 |
x 2,4
4
In the Middle of an Expanding Specialty Pharma Market
5
Um den Rest dieser Noodl zu lesen, rufen Sie bitte die Originalversion auf, und zwar hier.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Eckert & Ziegler AG published this content on 11 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2022 17:11:06 UTC.